169 related articles for article (PubMed ID: 37987099)
1. Body composition parameters predict survival in pancreatic cancer-A retrospective multicenter analysis.
Damm M; Efremov L; Jalal M; Nadeem N; Dober J; Michl P; Wohlgemuth WA; Wadsley J; Hopper AD; Krug S; Rosendahl J
United European Gastroenterol J; 2023 Dec; 11(10):998-1009. PubMed ID: 37987099
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study.
Keyl J; Bucher A; Jungmann F; Hosch R; Ziller A; Armbruster R; Malkomes P; Reissig TM; Koitka S; Tzianopoulos I; Keyl P; Kostbade K; Albers D; Markus P; Treckmann J; Nassenstein K; Haubold J; Makowski M; Forsting M; Baba HA; Kasper S; Siveke JT; Nensa F; Schuler M; Kaissis G; Kleesiek J; Braren R
ESMO Open; 2024 Jan; 9(1):102219. PubMed ID: 38194881
[TBL] [Abstract][Full Text] [Related]
3. Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.
Nowak S; Kloth C; Theis M; Marinova M; Attenberger UI; Sprinkart AM; Luetkens JA
Eur Radiol; 2024 Jan; 34(1):279-286. PubMed ID: 37572195
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer.
Salinas-Miranda E; Deniffel D; Dong X; Healy GM; Khalvati F; O'Kane GM; Knox J; Bathe OF; Baracos VE; Gallinger S; Haider MA
Eur Radiol; 2021 Nov; 31(11):8662-8670. PubMed ID: 33934171
[TBL] [Abstract][Full Text] [Related]
6. Prognosis prediction and comparison between pancreatic signet ring cell carcinoma and pancreatic duct adenocarcinoma: a retrospective observational study.
Zhou H; Li XX; Huang YP; Wang YX; Zou H; Xiong L; Liu ZT; Wen Y; Zhang ZJ
Front Endocrinol (Lausanne); 2023; 14():1205594. PubMed ID: 37534212
[TBL] [Abstract][Full Text] [Related]
7. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.
Rollins KE; Tewari N; Ackner A; Awwad A; Madhusudan S; Macdonald IA; Fearon KC; Lobo DN
Clin Nutr; 2016 Oct; 35(5):1103-9. PubMed ID: 26411749
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
[TBL] [Abstract][Full Text] [Related]
9. Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy.
Sahin TK; Ozbay Y; Altunbulak AY; Altunbulak HI; Onur MR; Ceylan F; Guven DC; Yalcin S; Dizdar O
Int J Clin Oncol; 2024 Jun; 29(6):822-831. PubMed ID: 38565751
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
11. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
12. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
13. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
14. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
[TBL] [Abstract][Full Text] [Related]
15. Elevated preoperative plasma D-dimer level was an independent prognostic factor for patients with PDAC after curative resection: a retrospective analysis.
Zhifei L; Yuexiang L; Shaofei C; Shuo L; Hongwei W; Chuntao G
Jpn J Clin Oncol; 2023 Nov; 53(11):1058-1067. PubMed ID: 37539583
[TBL] [Abstract][Full Text] [Related]
16. Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nakajo M; Maemura K; Arima S; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1679-1689. PubMed ID: 31728691
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Kim DW; Ahn H; Kim KW; Lee SS; Kim HJ; Ko Y; Park T; Lee J
Korean J Radiol; 2022 Nov; 23(11):1055-1066. PubMed ID: 36098341
[TBL] [Abstract][Full Text] [Related]
18. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
19. CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients.
Sun Y; Wu G; Cheng KS; Chen A; Neoh KH; Chen S; Tang Z; Lee PF; Dai M; Han RPS
EBioMedicine; 2019 Aug; 46():133-149. PubMed ID: 31375425
[TBL] [Abstract][Full Text] [Related]
20. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.
Lembeck AL; Posch F; Klocker EV; Szkandera J; Schlick K; Stojakovic T; Kornprat P; Lackner C; Gerger A; Stoeger H; Stotz M; Pichler M
Clin Chem Lab Med; 2019 Apr; 57(5):740-744. PubMed ID: 30307891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
